Department of Health and Human Services October 19, 2010 – Federal Register Recent Federal Regulation Documents

National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting
Document Number: 2010-26321
Type: Notice
Date: 2010-10-19
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting
Document Number: 2010-26320
Type: Notice
Date: 2010-10-19
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings
Document Number: 2010-26318
Type: Notice
Date: 2010-10-19
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Document Number: 2010-26317
Type: Notice
Date: 2010-10-19
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings
Document Number: 2010-26316
Type: Notice
Date: 2010-10-19
Agency: Department of Health and Human Services, National Institutes of Health
National Eye Institute; Notice of Closed Meeting
Document Number: 2010-26310
Type: Notice
Date: 2010-10-19
Agency: Department of Health and Human Services, National Institutes of Health
Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting
Document Number: 2010-26251
Type: Notice
Date: 2010-10-19
Agency: Food and Drug Administration, Department of Health and Human Services
Oncologic Drugs Advisory Committee; Notice of Meeting
Document Number: 2010-26247
Type: Notice
Date: 2010-10-19
Agency: Food and Drug Administration, Department of Health and Human Services
Notice of Meeting; National Commission on Children and Disasters
Document Number: 2010-26231
Type: Notice
Date: 2010-10-19
Agency: Department of Health and Human Services, Administration for Children and Families, Children and Families Administration
Components for Evaluation of Direct-Reading Monitors for Gases and Vapors and Addendum
Document Number: 2010-26221
Type: Notice
Date: 2010-10-19
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the availability of the following draft publication for public comment. The document and its addendum are entitled, respectively, ``Components for Evaluation of Direct-Reading Monitors for Gases and Vapors'' and ``Addendum to Components for Evaluation of Direct-Reading Monitors for Gases and Vapors: Hazard Detection in First Responder Environments.'' The draft documents and instructions for submitting comments can be found at: https://www.cdc.gov/niosh/docket/ review/docket220. The document expands the 1995 method development and evaluation experimental testing methods to direct-reading monitors for gases and vapors. These Components are provided for laboratory users, consensus standard setting bodies, and manufacturers of direct-reading instrumentation and are compatible with the Instrumentation, Systems, and Automation Society guidelines. The addendum to the document expands the applicability of the Components by presenting methods to be used in evaluating direct-reading monitors for hazard detection in First Responder environments. The 1995 document, entitled ``Guidelines for Air Sampling and Analytical Method Development and Evaluation,'' can be viewed at: https://www.cdc.gov/niosh/docs/ 95-117/. This guidance does not have the force and effect of the law.
Determination That BUSPAR (Buspirone Hydrochloride) Tablets, 10 Milligrams, 15 Milligrams, and 30 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Document Number: 2010-26214
Type: Notice
Date: 2010-10-19
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) has determined that BUSPAR (buspirone hydrochloride) Tablets, 10 milligrams (mg), 15 mg, and 30 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
Product Development Program for Interventions in Patients With Severe Bleeding Due to Trauma or Other Causes; Public Workshop
Document Number: 2010-26212
Type: Notice
Date: 2010-10-19
Agency: Food and Drug Administration, Department of Health and Human Services
Advisory Committee on Training in Primary Care Medicine and Dentistry; Notice of Meeting
Document Number: 2010-26205
Type: Notice
Date: 2010-10-19
Agency: Department of Health and Human Services, Health Resources and Services Administration
National Advisory Council on Nurse Education and Practice; Notice of Meeting
Document Number: 2010-26204
Type: Notice
Date: 2010-10-19
Agency: Department of Health and Human Services, Health Resources and Services Administration
Advisory Committee on Interdisciplinary, Community-Based Linkages; Notice of Meeting
Document Number: 2010-26203
Type: Notice
Date: 2010-10-19
Agency: Department of Health and Human Services, Health Resources and Service Administration, Health Resources and Services Administration
National Toxicology Program (NTP); Office of Liaison, Policy and Review Meeting of the NTP Board of Scientific Counselors
Document Number: 2010-26023
Type: Notice
Date: 2010-10-19
Agency: Department of Health and Human Services, National Institutes of Health
Pursuant to Public Law 92-463, notice is hereby given of a meeting of the NTP Board of Scientific Counselors (BSC). The BSC is a federally chartered, external advisory group composed of scientists from the public and private sectors that provides primary scientific oversight to the NTP Director and evaluates the scientific merit of the NTP's intramural and collaborative programs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.